Short Interest in Inspire Medical Systems (NYSE:INSP) Expands By 19.5%
Inspire Medical Systems (NYSE:INSP) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,470,000 shares, a growth of 19.5% from the January 15th total of 1,230,000 shares. Currently, 7.2% of the company’s shares are sold short. Based on an average daily trading volume, of 217,800 shares, the short-interest ratio is presently 6.7 days.
Shares of NYSE:INSP traded up $0.79 during midday trading on Friday, hitting $81.17. The company had a trading volume of 168,016 shares, compared to its average volume of 297,830. Inspire Medical Systems has a 12 month low of $46.00 and a 12 month high of $83.71. The company has a current ratio of 13.42, a quick ratio of 13.05 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -65.99 and a beta of 1.27. The firm has a fifty day simple moving average of $77.71 and a 200 day simple moving average of $67.94.
In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 9,832 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $80.10, for a total value of $787,543.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jerry C. Griffin sold 5,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $81.92, for a total value of $409,600.00. Following the completion of the transaction, the director now owns 31,812 shares in the company, valued at $2,606,039.04. The disclosure for this sale can be found here. Insiders sold a total of 111,409 shares of company stock worth $8,174,624 over the last quarter. Corporate insiders own 12.10% of the company’s stock.
Several research analysts have recently issued reports on the company. Berenberg Bank upgraded Inspire Medical Systems from a “sell” rating to a “hold” rating and raised their price target for the stock from $46.00 to $51.00 in a research report on Wednesday, November 6th. Oppenheimer assumed coverage on Inspire Medical Systems in a research report on Monday, January 27th. They issued an “underperform” rating and a $50.00 price target on the stock. Zacks Investment Research lowered Inspire Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, January 4th. Wells Fargo & Co raised their price target on Inspire Medical Systems from $70.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, January 16th. Finally, ValuEngine upgraded Inspire Medical Systems from a “sell” rating to a “hold” rating in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Inspire Medical Systems has a consensus rating of “Hold” and a consensus target price of $68.83.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Recommended Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.